272 related articles for article (PubMed ID: 20880333)
1. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen.
Ohno M; Natsume A; Ichiro Iwami K; Iwamizu H; Noritake K; Ito D; Toi Y; Ito M; Motomura K; Yoshida J; Yoshikawa K; Wakabayashi T
Cancer Sci; 2010 Dec; 101(12):2518-24. PubMed ID: 20880333
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.
Kuramitsu S; Ohno M; Ohka F; Shiina S; Yamamichi A; Kato A; Tanahashi K; Motomura K; Kondo G; Kurimoto M; Senga T; Wakabayashi T; Natsume A
Cancer Gene Ther; 2015 Oct; 22(10):487-95. PubMed ID: 26450624
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
[TBL] [Abstract][Full Text] [Related]
4. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells.
Morgenroth A; Cartellieri M; Schmitz M; Günes S; Weigle B; Bachmann M; Abken H; Rieber EP; Temme A
Prostate; 2007 Jul; 67(10):1121-31. PubMed ID: 17492652
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
Lammering G; Hewit TH; Holmes M; Valerie K; Hawkins W; Lin PS; Mikkelsen RB; Schmidt-Ullrich RK
Clin Cancer Res; 2004 Oct; 10(19):6732-43. PubMed ID: 15475464
[TBL] [Abstract][Full Text] [Related]
6. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells.
Mezzanzanica D; Canevari S; Mazzoni A; Figini M; Colnaghi MI; Waks T; Schindler DG; Eshhar Z
Cancer Gene Ther; 1998; 5(6):401-7. PubMed ID: 9917095
[TBL] [Abstract][Full Text] [Related]
7. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
8. Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma.
Sonabend AM; Dana K; Lesniak MS
Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S45-50. PubMed ID: 18076318
[TBL] [Abstract][Full Text] [Related]
9. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
Kuan CT; Reist CJ; Foulon CF; Lorimer IA; Archer G; Pegram CN; Pastan I; Zalutsky MR; Bigner DD
Clin Cancer Res; 1999 Jun; 5(6):1539-49. PubMed ID: 10389943
[TBL] [Abstract][Full Text] [Related]
10. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
Moeller M; Haynes NM; Trapani JA; Teng MW; Jackson JT; Tanner JE; Cerutti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
Cancer Gene Ther; 2004 May; 11(5):371-9. PubMed ID: 15060573
[TBL] [Abstract][Full Text] [Related]
11. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
12. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.
Wikstrand CJ; McLendon RE; Friedman AH; Bigner DD
Cancer Res; 1997 Sep; 57(18):4130-40. PubMed ID: 9307304
[TBL] [Abstract][Full Text] [Related]
13. The T-body approach: redirecting T cells with antibody specificity.
Eshhar Z
Handb Exp Pharmacol; 2008; (181):329-42. PubMed ID: 18071952
[TBL] [Abstract][Full Text] [Related]
14. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
15. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
Morgan RA; Johnson LA; Davis JL; Zheng Z; Woolard KD; Reap EA; Feldman SA; Chinnasamy N; Kuan CT; Song H; Zhang W; Fine HA; Rosenberg SA
Hum Gene Ther; 2012 Oct; 23(10):1043-53. PubMed ID: 22780919
[TBL] [Abstract][Full Text] [Related]
16. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes.
Altenschmidt U; Kahl R; Moritz D; Schnierle BS; Gerstmayer B; Wels W; Groner B
Clin Cancer Res; 1996 Jun; 2(6):1001-8. PubMed ID: 9816261
[TBL] [Abstract][Full Text] [Related]
17. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
18. [Cellular immunotherapy for malignant glioma].
Okamoto Y; Yamashita J
Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
[No Abstract] [Full Text] [Related]
19. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
Wikstrand CJ; Hale LP; Batra SK; Hill ML; Humphrey PA; Kurpad SN; McLendon RE; Moscatello D; Pegram CN; Reist CJ
Cancer Res; 1995 Jul; 55(14):3140-8. PubMed ID: 7606735
[TBL] [Abstract][Full Text] [Related]
20. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.
Lo AS; Ma Q; Liu DL; Junghans RP
Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]